Cardiovascular Diabetology

1. Cardiovasc Diabetol11 Jul 2026

   Henagliflozin attenuates adverse ventricular remodeling and improves cardiometabolic parameters in patients with type 2 diabetes and hypertension: real-world evidence from a propensity score-matched analysis

   Cohort studyT2D & other

2. Cardiovasc Diabetol9 Jul 2026

   Comparative effectiveness of dual antiplatelet therapy after revascularization in diabetes and chronic limb-threatening ischemia: a target trial emulation study

   Cohort studyT2D & other

3. Cardiovasc Diabetol8 Jul 2026

   STIM1-dependent treg dysfunction promotes cardiometabolic HFpEF: insights from patients and animal studies

   Mechanistic study

4. Cardiovasc Diabetol7 Jul 2026

   Association of C-reactive protein-triglyceride glucose index and its modified indices with stroke risk in individuals at cardiovascular-kidney-metabolic syndrome stages 0–3: a population-based cohort study

   Cohort study

5. Cardiovasc Diabetol6 Jul 2026

   Joint association of Insulin resistance and frailty index with incident ASCVD and MACE in individuals with cardiovascular-kidney-metabolic syndrome stages 0–3: a multi-cohort study

   Cohort study

6. Cardiovasc Diabetol6 Jul 2026

   Glucagon-like peptide-1 receptor agonists and major limb events in adults with type 2 diabetes and peripheral artery disease: a systematic review and meta-analysis of RCTs and cohort studies

   Meta-analysisT2D & other

7. Cardiovasc Diabetol5 Jul 2026

   Joint longitudinal trajectories of the triglyceride-glucose index combined with BMI and waist-to-height ratio and incident cardiovascular disease: a prospective cohort study from the English longitudinal study of ageing

   Cohort studyObesity

8. Cardiovasc Diabetol4 Jul 2026

   Comparative performance of insulin resistance-related indices in predicting adverse cardiovascular events among individuals with NAFLD and MASLD: a multi-center cohort study

   Cohort studyLipids & liver

9. Cardiovasc Diabetol4 Jul 2026

   Synergistic SGLT2 and GLP-1R targeting alleviates systemic inflammation-induced and M1 monocyte-driven endothelial dysfunction in coronary artery disease

   Mechanistic studyT2D & other

10. Cardiovasc Diabetol1 Jul 2026

    Opportunistic screening for incident cardiometabolic disease in metabolically healthy non-obese individuals: a prospective cohort study

    Cohort studyObesity

11. Cardiovasc Diabetol1 Jul 2026

    Insulin resistance surrogate indices and incident cardiovascular disease across cardiovascular–kidney–metabolic stages 0–3: a prospective cohort study

    Cohort study

12. Cardiovasc Diabetol29 Jun 2026

    Deep learning analysis of ECGs detects Cardiovascular–Kidney–Metabolic syndrome burden in people with diabetes: a report from the Silesia Diabetes-Heart Project

    Diagnostic or prognostic studyT2D & other

13. Cardiovasc Diabetol29 Jun 2026

    Association of the atherogenic index of plasma and its integrative novel adiposity-based composites with all-cause and cardiovascular mortality in individuals with cardiovascular-kidney-metabolic syndrome: novel adiposity-derived AIP indices provide modest incremental prognostic information

    Cohort studyLipids & liver

14. Cardiovasc Diabetol28 Jun 2026

    Correlation between surrogate indicators of insulin resistance and all-cause mortality in patients with severe hemorrhagic stroke: a multicenter retrospective cohort study in the United States

    Cohort studyComplications

15. Cardiovasc Diabetol28 Jun 2026

    Integrating lipometabolic and adiposity indices to enhance risk stratification for metabolic dysfunction-associated steatotic liver disease in type 2 diabetes: clinical utility and interplay between triglyceride-glucose body mass index and low-density lipoprotein cholesterol

    Diagnostic or prognostic studyT2D & other

16. Cardiovasc Diabetol26 Jun 2026

    Associations of cumulative exposure and longitudinal change patterns of the triglyceride glucose–Chinese visceral adiposity index with incident cardiovascular disease in middle-aged and older adults: evidence from CHARLS

    Cohort studyComplications

17. Cardiovasc Diabetol23 Jun 2026

    Cardiovascular-liver-metabolic multimorbidity: preliminary insights into the associations with the triglyceride glucose index (TyG), its obesity-derived indices and their effects on long-term survival

    Cohort studyObesity

18. Cardiovasc Diabetol23 Jun 2026

    Association between insulin resistance surrogate markers and cardiovascular disease risk in individuals with subclinical metabolic disorders: a prospective cohort study based on baseline levels, cumulative exposure, and longitudinal trajectories

    Cohort studyT2D & other

19. Cardiovasc Diabetol22 Jun 2026

    Associations of insulin resistance-related indices with the risk and progression of cardiometabolic multimorbidity in individuals with metabolic dysfunction-associated steatotic liver disease: a prospective cohort study

    Cohort studyLipids & liver

20. Cardiovasc Diabetol22 Jun 2026

    Burden trajectories of stroke attributable to lipid-glucose dysfunction and biomarker validation: evidence from the global burden of disease (GBD) 2023 and the China health and retirement longitudinal study (CHARLS)

    Secondary analysisLipids & liver

21. Cardiovasc Diabetol22 Jun 2026

    An interpretable machine learning model for predicting postoperative hypotension in type 2 diabetes mellitus undergoing non‑cardiac surgery

    Diagnostic or prognostic studyT2D & other

22. Cardiovasc Diabetol21 Jun 2026

    Optimizing early triage for subclinical cardiovascular-kidney-metabolic syndrome: longitudinal associations, incremental value, and clinical utility of nine insulin resistance surrogates

    Cohort studyT2D & other

23. Cardiovasc Diabetol20 Jun 2026

    Cumulative exposure and longitudinal exposure pattern of C-reactive protein-triglyceride-glucose index combined with Chinese visceral adiposity index (CTI-CVAI) and the risk of new-onset cardiovascular disease in middle-aged and older Chinese adults: a prospective cohort study based on the China Health and Retirement Longitudinal Survey (CHARLS)

    Cohort studyComplications

24. Cardiovasc Diabetol20 Jun 2026

    Associations between the C-reactive protein-triglyceride-glucose index and its derived indices and the incidence and progression of cardiometabolic multimorbidity in participants with metabolic dysfunction-associated steatotic liver disease: a large-scale prospective cohort study

    Cohort studyLipids & liver

25. Cardiovasc Diabetol20 Jun 2026

    Proteomics of multimorbidity progression across cardiometabolic diseases and cancer in a multinational cohort

    Cohort studyT2D & other

26. Cardiovasc Diabetol20 Jun 2026

    Targeted proteomics of extreme vascular phenotypes in type 1 diabetes: the ESCAPER study

    Cross-sectional studyComplications

27. Cardiovasc Diabetol19 Jun 2026

    Longitudinal variability of lipoprotein(a) in youth-onset type 1 diabetes: implications for cardiovascular risk stratification

    Cohort studyT1D

28. Cardiovasc Diabetol18 Jun 2026

    Predictive significance of triglyceride-glucose index in forecasting adverse cardiovascular events among Type 2 diabetes mellitus patients with co-existing metabolic dysfunction-associated steatotic liver disease (MASLD): evidence from two cohort studies

    Cohort studyT2D & other

29. Cardiovasc Diabetol17 Jun 2026

    Hemoglobin glycation index may contextualize the association between time-varying stress hyperglycemia ratio and mortality in critically ill patients with heart failure: a multicenter retrospective cohort study

    Cohort study

30. Cardiovasc Diabetol17 Jun 2026

    Exercise modalities and dosages on glycated haemoglobin and exerkines in type 2 diabetes: a systematic review with pairwise, network, and dose-response meta-analyses

    Meta-analysisT2D & other

31. Cardiovasc Diabetol16 Jun 2026

    Cardioprotective glucose-lowering drugs, statins, and secondary major adverse cardiovascular events: a nationwide cohort study of individuals with type 2 diabetes and cardiovascular disease

    Cohort studyT2D & other

32. Cardiovasc Diabetol16 Jun 2026

    Integration of triglyceride-glucose index and biological aging to predict cardiovascular disease risk in cardiovascular–kidney–metabolic syndrome stages 0–3: a multiple prospective cohort study

    Cohort studyComplications

33. Cardiovasc Diabetol15 Jun 2026

    Head-to-head comparison of fasting-insulin-based versus non-insulin-based insulin resistance surrogates for predicting all-cause and cardiovascular mortality in hypertensive adults across the glycemic continuum: a prospective cohort study

    Cohort studyT2D & other

34. Cardiovasc Diabetol15 Jun 2026

    Prognostic Value of Coronary CT Angiography Among Patients With and Without Diabetes: The Mass General Brigham CCTA registry

    Cohort studyT2D & other

35. Cardiovasc Diabetol14 Jun 2026

    Associations of the atherogenic index of plasma and its modified indices with the incidence and progression of cardiometabolic multimorbidity in individuals with cardiovascular-kidney-metabolic syndrome stages 0–3: a prospective cohort study

    Cohort studyT2D & other

36. Cardiovasc Diabetol13 Jun 2026

    Association of fat-to-muscle mass ratio with incident coronary artery disease and the potential role of metabolic signatures

    Cohort studyComplications

37. Cardiovasc Diabetol12 Jun 2026

    Apolipoprotein B100 predicts cardiovascular and limb events in type 2 diabetes patients with chronic limb-threatening ischemia

    Cohort studyT2D & other

38. Cardiovasc Diabetol12 Jun 2026

    The effect of empagliflozin on inflammation in patients with overweight or obesity and risk of heart failure: a substudy from the Empire Prevent Metabolic trial

    Secondary analysisObesity

39. Cardiovasc Diabetol12 Jun 2026

    Growth differentiation factor-15 and the incidence, bidirectional progression, and risk prediction of atherosclerotic cardiovascular disease and metabolic dysfunction-associated steatotic liver disease in individuals with cardiovascular-kidney-metabolic syndrome stages 0–3

    Cohort studyLipids & liver

40. Cardiovasc Diabetol12 Jun 2026

    Integrating inflammation, insulin resistance, and visceral adiposity: the C-reactive protein–triglyceride–glucose-Chinese visceral adiposity (CTI–CVAI) index is associated with cardiovascular disease risk across CKM stages 0–3 in a nationwide prospective cohort

    Cohort studyT2D & other

All 1,291 Briefs in ExploreShowing Briefs 41–80 of 1,291, newest first